Phase I/II Study of Oblimersen, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Patients With Advanced Colorectal Cancer
Last Modified: 3/1/2005  First Published: 2/21/2003
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
SACI-IDD-02-23 NCI-5793, NCT00055822, 5793
|
|
|
Objectives - Determine the maximum tolerated dose of oblimersen when administered with oxaliplatin, fluorouracil, and leucovorin calcium in patients with advanced colorectal cancer.
- Determine the quantitative and qualitative toxic effects of this regimen in these patients.
- Determine the antitumor activity of this regimen in these patients.
- Determine the plasma pharmacokinetics of oblimersen and oxaliplatin in patients treated with this regimen.
- Determine relevant predictive biomarkers of response in patients treated with this regimen.
Entry Criteria Disease Characteristics:
- Histologically or cytologically confirmed adenocarcinoma of the colon or rectum
- Unresectable, metastatic, or recurrent disease
- Measurable or evaluable disease (phase I)
- Measurable disease (phase II)
- No known brain metastases
- Patients with previously treated brain metastases who are not currently receiving steroids and have a stable CT scan or MRI are eligible
Prior/Concurrent Therapy:
Biologic therapy - No concurrent epoetin alfa during course 1
- No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF)
- No concurrent immunotherapy
Chemotherapy - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- No prior oxaliplatin
- No other concurrent chemotherapy
Endocrine therapy - See Disease Characteristics
Radiotherapy - At least 4 weeks since prior radiotherapy and recovered
- No concurrent radiotherapy
Surgery Other - No prior oblimersen
- No other concurrent investigational agents
- No other concurrent antitumor therapy
Patient Characteristics:
Age Performance status - ECOG 0-2
OR - Karnofsky 60-100%
Life expectancy Hematopoietic - Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- Hemoglobin at least 9 g/dL
Hepatic - Bilirubin no greater than 1.5 mg/dL
- AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
- INR no greater than 1.5 times ULN (unless currently receiving anticoagulant therapy)
- PT/PTT no greater than 1.5 times ULN (unless currently receiving anticoagulant therapy)
Renal - Creatinine normal
OR - Creatinine clearance at least 60 mL/min
Cardiovascular - No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No history of allergic reaction to compounds of similar chemical or biologic composition to fluorouracil or oxaliplatin
- No other concurrent uncontrolled medical condition that would preclude study participation
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study compliance
- No known history of degenerative facet disease during prior fluorouracil therapy
- No HIV-positive patients receiving combination antiretroviral therapy
Expected Enrollment A total of 6-53 patients (6-18 patients for phase I and 12-35 patients for phase II) will be accrued for this study. Outline This is an open-label, phase I, dose-escalation study of oblimersen followed by a non-randomized, phase II study. In both phases, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed at 30 days.
Trial Contact Information
Trial Lead Organizations San Antonio Cancer Institute | | | Anthony Tolcher, MD, Protocol chair | | | |
Registry Information | | Official Title | | A Phase I/II Study of Oblimersen Sodium (G3139, Genasense) in Combination with Oxaliplatin, 5FU and Leucovorin (FOLFOX4) Regimen in Advanced Colorectal Cancer | | Trial Start Date | | 2002-10-25 | | Registered in ClinicalTrials.gov | | NCT00055822 1 | | Date Submitted to PDQ | | 2003-01-17 | | Information Last Verified | | 2005-03-01 | | NCI Grant/Contract Number | | U01-CA69853 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.
Table of Links
1 | http://clinicaltrials.gov/ct/show/NCT00055822 |
|